Filing Flows › Orthopediatrics (KIDS) › Q2 2025
Orthopediatrics (KIDS) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 6, 2025
Orthopediatrics (KIDS) reported revenue of $61.1M for the second quarter 2025 (Q2 2025), +16% from a year earlier and +17% from the quarter before. Operating margin was -17.4%, net loss $7.1M (11.6% of revenue).
Orthopediatrics, Q2 2025: revenue $61.1M (+16% year over year), operating margin -17.4%, net loss $7.1M, operating cash flow −$10.5M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $61.1M | +17% | +16% |
| Operating profit | −$10.7M | — | — |
| Net earnings | −$7.1M | — | — |
| Operating cash flow | −$10.5M | — | — |
What changed
Revenue was $61.1M in Q2 2025, up 16% year over year and up 17% from the previous quarter. Trauma and deformity was the largest line at 68% of revenue. Scoliosis added $4.8M year over year (up 35%), 58% of the total change. Sports medicine/other declined 33%.
Gross margin was 72.1%, down 5.2 points from a year earlier. Operating costs exceeded revenue by $10.7M, an operating margin of -17.4%. Operating expenses grew 18% against revenue growth of 16%. The fastest-growing cost line was Sales & marketing (+15%). The quarter ended with a net loss of $7.1M, narrower than the previous quarter's $10.7M loss. Non-operating items added $3.6M, -51% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$10.5M. Non-cash charges added back $5.2M of depreciation and amortization and $5.3M of share-based compensation. Working capital and other items used $13.8M. Capital expenditures of $3.4M exceeded it, leaving free cash flow of −$13.9M.
Questions
What was Orthopediatrics' revenue in the second quarter 2025?
Orthopediatrics (KIDS) reported revenue of $61.1M for the second quarter 2025 (Q2 2025), +16% from a year earlier and +17% from the quarter before.
Was Orthopediatrics profitable in the second quarter 2025?
Operating loss was $10.7M (-17.4% of revenue) and net loss $7.1M.
Source: Orthopediatrics 10-Q on SEC EDGAR.